Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:LUMO

Lumos Pharma (LUMO) Stock Price, News & Analysis

Lumos Pharma logo

About Lumos Pharma Stock (NASDAQ:LUMO)

Advanced Chart

Key Stats

Today's Range
$4.34
$4.34
50-Day Range
$4.30
$4.41
52-Week Range
$1.39
$4.58
Volume
N/A
Average Volume
97,277 shs
Market Capitalization
$37.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.63
Consensus Rating
Buy

Company Overview

Receive LUMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lumos Pharma and its competitors with MarketBeat's FREE daily newsletter.

LUMO Stock News Headlines

Lumos Pharma Completes Merger and Delisting Process
Google did what!?!?
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
Lumos Pharma reports sustained growth in PGHD trials
Lumos announces new analyses of data from OraGrowtH210, OraGrowtH212 trials
See More Headlines

LUMO Stock Analysis - Frequently Asked Questions

Lumos Pharma, Inc. (NASDAQ:LUMO) announced its quarterly earnings results on Thursday, November, 7th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by $0.34. The firm earned $0.73 million during the quarter, compared to the consensus estimate of $0.50 million. Lumos Pharma had a negative trailing twelve-month return on equity of 233.03% and a negative net margin of 1,583.49%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lumos Pharma investors own include uniQure (QURE), Clean Energy Fuels (CLNE), ACADIA Pharmaceuticals (ACAD), Bicycle Therapeutics (BCYC), Curaleaf (CURLF), Paycom Software (PAYC) and VALE (VALE).

Company Calendar

Last Earnings
11/07/2024
Today
7/15/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LUMO
CIK
1126234
Employees
30
Year Founded
N/A

Price Target and Rating

High Price Target
$13.00
Low Price Target
$4.25
Potential Upside/Downside
+98.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.29)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$34.03 million
Net Margins
-1,583.49%
Pretax Margin
-1,583.49%
Return on Equity
-233.03%
Return on Assets
-129.88%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.66
Quick Ratio
2.66

Sales & Book Value

Annual Sales
$2.21 million
Price / Sales
17.02
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.45 per share
Price / Book
1.26

Miscellaneous

Outstanding Shares
8,649,000
Free Float
6,452,000
Market Cap
$37.54 million
Optionable
Not Optionable
Beta
0.74
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:LUMO) was last updated on 7/15/2025 by MarketBeat.com Staff
From Our Partners